Direxion Daily Phrmctcl&MdclBl3XShrsETF (PILL)
7.86
+0.32
(+4.24%)
USD |
NYSEARCA |
Jul 26, 16:00
7.86
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 1.01% | -0.12% | 15.85M | 82460.87 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 1.56% | 51.00% | 4.923M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Growth and Income |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 6.63 yrs |
| Tony Ng | 6.63 yrs |
Performance Versus Category
As of July 25, 2024. Returns for periods above 1 year are annualized.
Annual Total Returns Versus Peers
As of July 25, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Growth and Income |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 6.63 yrs |
| Tony Ng | 6.63 yrs |